0.6276
2.86%
-0.0185
Citius Pharmaceuticals Inc stock is currently priced at $0.6276, with a 24-hour trading volume of 407.22K.
It has seen a -2.86% decreased in the last 24 hours and a -9.74% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.6454 pivot point. If it approaches the $0.6158 support level, significant changes may occur.
Previous Close:
$0.6461
Open:
$0.635
24h Volume:
407.22K
Market Cap:
$113.39M
Revenue:
-
Net Income/Loss:
$-32.54M
P/E Ratio:
-3.138
EPS:
-0.2
Net Cash Flow:
$-29.06M
1W Performance:
-0.65%
1M Performance:
-9.74%
6M Performance:
-21.53%
1Y Performance:
-50.19%
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Name
Citius Pharmaceuticals Inc
Sector
Industry
Phone
908-967-6677
Address
11 Commerce Drive, First Floor, Cranford, NJ
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-30-21 | Initiated | Maxim Group | Buy |
Citius Pharmaceuticals Inc Stock (CTXR) Latest News
Perhaps timely catching Citius Pharmaceuticals Inc (CTXR) would be a good idea – Sete News - SETE News
SETE News
Citius Pharmaceuticals Inc (CTXR)'s highs and lows: A closer look at its stock price fluctuations – US Post News - US Post News
US Post News
Citius Pharmaceuticals Inc (CTXR) expanding its growth trajectory ahead – Sete News - SETE News
SETE News
Stock Performance Spotlight: Citius Pharmaceuticals Inc (CTXR) Ends the Day at 0.70, Up by 6.39 – DWinneX - The Dwinnex
The Dwinnex
Citius Pharmaceuticals' (CTXR) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
MarketBeat
Citius Pharmaceuticals (NASDAQ:CTXR) Rating Reiterated by HC Wainwright - MarketBeat
MarketBeat
Citius Pharmaceuticals Inc Stock (CTXR) Financials Data
Citius Pharmaceuticals Inc (CTXR) Net Income 2024
CTXR net income (TTM) was -$32.54 million for the quarter ending September 30, 2023, a +3.26% increase year-over-year.
Citius Pharmaceuticals Inc (CTXR) Cash Flow 2024
CTXR recorded a free cash flow (TTM) of -$29.06 million for the quarter ending September 30, 2023, a -2.46% decrease year-over-year.
Citius Pharmaceuticals Inc (CTXR) Earnings per Share 2024
CTXR earnings per share (TTM) was -$0.22 for the quarter ending September 30, 2023, a 0.00% decline year-over-year.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido product, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Cap:
|
Volume (24h):